Alyeska Investment Group
DYN icon

Alyeska Investment Group’s Dyne Therapeutics DYN Stock Holding History

Alyeska Investment Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$882K – 574
2024
Q2 		$882K Buy
+25,000
New +$726K 0.01% 469
2021
Q3 		– Sell
-125,566
Closed -$2.64M – 707
2021
Q2 		$2.64M Hold
125,566
– – 0.03% 463
2021
Q1 		$1.95M Buy
125,566
+47,000
+60% +$910K 0.03% 485
2020
Q4 		$1.65M Buy
78,566
+49,371
+169% +$977K 0.02% 389
2020
Q3 		$589K Buy
+29,195
New +$641K 0.01% 411

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group's DYN Position: Q3 2024 in Review

Alyeska Investment Group sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 25,000 shares — an estimated $882K sold.

Alyeska Investment Group first reported a position in DYN in Q3 2020 and held it in 5 quarters. The position peaked at $2.64M in Q2 2021. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Alyeska Investment Group reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 25,000 Dyne Therapeutics shares in Q3 2024, an estimated $882K.
  • Alyeska Investment Group first reported a position in Dyne Therapeutics in Q3 2020 and held it in 5 quarters.
  • Alyeska Investment Group's Dyne Therapeutics position peaked at $2.64M in Q2 2021.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.